Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Selley

Showing results (101-110 of 149) with videos related to

Pageof 15
Sort By:
Neuropharmacology|January 10, 2020
Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathyDana E Selley, Matthew F Lazenka, Laura J Sim-Selley, et al.
Journal of Medicinal Chemistry|May 24, 2021
Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 InfectivityBoshi Huang, Huiqun Wang, Yi Zheng, et al.
Journal of Medicinal Chemistry|October 23, 2013
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivityYunyun Yuan, Saheem A Zaidi, Orgil Elbegdorj, et al.
ACS Chemical Neuroscience|July 21, 2012
Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonistsYunyun Yuan, Guo Li, Hengjun He, et al.
Journal of Medicinal Chemistry|December 20, 2022
Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG ToxicityHongguang Ma, Piyusha P Pagare, Mengchu Li, et al.
Journal of Neurochemistry|January 5, 2013
Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systemsLawrence C Blume, Caroline E Bass, Steven R Childers, et al.
Journal of Medicinal Chemistry|February 10, 2009
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonistsGuo Li, Lindsey C Aschenbach, Jianyang Chen, et al.
Neuropharmacology|January 26, 2016
Early adolescent nicotine exposure affects later-life cocaine reward in miceMai Alajaji, Matthew F Lazenka, Dena Kota, et al.
ACS Chemical Neuroscience|December 31, 2015
17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased FashionYan Zhang, Dwight A Williams, Saheem A Zaidi, et al.
Bioorganic Chemistry|May 26, 2024
Blocking potential metabolic sites on NAT to improve its safety profile while retaining the pharmacological profileRachael Flammia, Boshi Huang, Piyusha P Pagare, et al.
Pageof 15

Showing results (101-110 of 149) with videos related to

Sort By:
Pageof 15
Neuropharmacology|January 10, 2020
Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathyDana E Selley, Matthew F Lazenka, Laura J Sim-Selley, et al.
Journal of Medicinal Chemistry|May 24, 2021
Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 InfectivityBoshi Huang, Huiqun Wang, Yi Zheng, et al.
Journal of Medicinal Chemistry|October 23, 2013
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivityYunyun Yuan, Saheem A Zaidi, Orgil Elbegdorj, et al.
ACS Chemical Neuroscience|July 21, 2012
Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonistsYunyun Yuan, Guo Li, Hengjun He, et al.
Journal of Medicinal Chemistry|December 20, 2022
Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG ToxicityHongguang Ma, Piyusha P Pagare, Mengchu Li, et al.
Journal of Neurochemistry|January 5, 2013
Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systemsLawrence C Blume, Caroline E Bass, Steven R Childers, et al.
Journal of Medicinal Chemistry|February 10, 2009
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonistsGuo Li, Lindsey C Aschenbach, Jianyang Chen, et al.
Neuropharmacology|January 26, 2016
Early adolescent nicotine exposure affects later-life cocaine reward in miceMai Alajaji, Matthew F Lazenka, Dena Kota, et al.
ACS Chemical Neuroscience|December 31, 2015
17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased FashionYan Zhang, Dwight A Williams, Saheem A Zaidi, et al.
Bioorganic Chemistry|May 26, 2024
Blocking potential metabolic sites on NAT to improve its safety profile while retaining the pharmacological profileRachael Flammia, Boshi Huang, Piyusha P Pagare, et al.
Pageof 15